Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Evaluation of EGFR and RTK signaling in the electrotaxis of lung adenocarcinoma cells under direct-current electric field stimulation.

Tsai HF, Huang CW, Chang HF, Chen JJ, Lee CH, Cheng JY.

PLoS One. 2013 Aug 9;8(8):e73418. doi: 10.1371/journal.pone.0073418. eCollection 2013.

2.

Gene expression of human lung cancer cell line CL1-5 in response to a direct current electric field.

Huang CW, Chen HY, Yen MH, Chen JJ, Young TH, Cheng JY.

PLoS One. 2011;6(10):e25928. doi: 10.1371/journal.pone.0025928. Epub 2011 Oct 5.

3.

Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells.

Akca H, Tani M, Hishida T, Matsumoto S, Yokota J.

Lung Cancer. 2006 Oct;54(1):25-33. Epub 2006 Jul 26.

PMID:
16872715
4.

Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.

Dobashi Y, Suzuki S, Kimura M, Matsubara H, Tsubochi H, Imoto I, Ooi A.

Hum Pathol. 2011 Feb;42(2):214-26. doi: 10.1016/j.humpath.2010.05.025. Epub 2010 Oct 30.

PMID:
21040950
5.

DC electric fields direct breast cancer cell migration, induce EGFR polarization, and increase the intracellular level of calcium ions.

Wu D, Ma X, Lin F.

Cell Biochem Biophys. 2013;67(3):1115-25. doi: 10.1007/s12013-013-9615-7.

PMID:
23657921
6.

Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.

Takata M, Chikumi H, Miyake N, Adachi K, Kanamori Y, Yamasaki A, Igishi T, Burioka N, Nanba E, Shimizu E.

Cancer Biol Ther. 2012 Apr;13(6):369-78. doi: 10.4161/cbt.19238. Epub 2012 Apr 1.

PMID:
22313637
7.

Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.

Yoshida T, Okamoto I, Okabe T, Iwasa T, Satoh T, Nishio K, Fukuoka M, Nakagawa K.

Int J Cancer. 2008 Apr 1;122(7):1530-8.

8.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

9.

Naphtho[1,2-b]furan-4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells.

Su JC, Lin KL, Chien CM, Tseng CH, Chen YL, Chang LS, Lin SR.

Life Sci. 2010 Jan 30;86(5-6):207-13. doi: 10.1016/j.lfs.2009.12.006. Epub 2009 Dec 28.

PMID:
20036260
10.

Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.

Gan Y, Shi C, Inge L, Hibner M, Balducci J, Huang Y.

Oncogene. 2010 Sep 2;29(35):4947-58. doi: 10.1038/onc.2010.240. Epub 2010 Jun 21.

PMID:
20562913
11.

Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition.

Agelaki S, Spiliotaki M, Markomanolaki H, Kallergi G, Mavroudis D, Georgoulias V, Stournaras C.

Cancer Biol Ther. 2009 Aug;8(15):1470-7. Epub 2009 Aug 8.

PMID:
19483462
12.

EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation.

Yao W, Feng D, Bian W, Yang L, Li Y, Yang Z, Xiong Y, Zheng J, Zhai R, He J.

Amino Acids. 2012 Nov;43(5):2027-35. doi: 10.1007/s00726-012-1277-z. Epub 2012 Apr 4.

13.

Sphingosine-1-phosphate receptor-3 signaling up-regulates epidermal growth factor receptor and enhances epidermal growth factor receptor-mediated carcinogenic activities in cultured lung adenocarcinoma cells.

Hsu A, Zhang W, Lee JF, An J, Ekambaram P, Liu J, Honn KV, Klinge CM, Lee MJ.

Int J Oncol. 2012 May;40(5):1619-26. doi: 10.3892/ijo.2012.1379. Epub 2012 Feb 16.

14.

Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells.

Sutton P, Borgia JA, Bonomi P, Plate JM.

Mol Cancer. 2013 Jul 16;12:76. doi: 10.1186/1476-4598-12-76.

15.

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.

Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD.

Clin Exp Metastasis. 2008;25(8):843-54. doi: 10.1007/s10585-008-9200-4. Epub 2008 Aug 12.

PMID:
18696232
16.

Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.

Conde E, Angulo B, Tang M, Morente M, Torres-Lanzas J, Lopez-Encuentra A, Lopez-Rios F, Sanchez-Cespedes M.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):710-7.

17.

Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.

Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY, Chen JJ, Chen HW, Yang PC.

PLoS One. 2011;6(8):e23756. doi: 10.1371/journal.pone.0023756. Epub 2011 Aug 17.

18.

The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK, Bunn PA Jr.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805.

19.

TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma.

Pallier K, Cessot A, Côté JF, Just PA, Cazes A, Fabre E, Danel C, Riquet M, Devouassoux-Shisheboran M, Ansieau S, Puisieux A, Laurent-Puig P, Blons H.

PLoS One. 2012;7(1):e29954. doi: 10.1371/journal.pone.0029954. Epub 2012 Jan 17.

20.

[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1].

Zhang W, Zhang W, Wang L, Zheng J, Xiao F.

Zhongguo Fei Ai Za Zhi. 2011 May;14(5):385-90. doi: 10.3779/j.issn.1009-3419.2011.05.01. Chinese.

Items per page

Supplemental Content

Write to the Help Desk